Abnova Launches circRNA Sponge Catalog Products and Customized Services, Advancing circRNA Sponge-miRNA Interaction Analysis Research

 

Neihu, Taiwan (July 31, 2023)

 

Abnova announced the release of a brand new series of circRNA Sponge catalog products and customized services, aimed at accelerating research into the function of circRNA as miRNA Sponge. The investigation of circRNA Sponge and miRNA interactions has garnered significant attention, and Abnova, with its exceptional expertise in the RNA field, provides researchers with high-quality tools and tailor-made services to facilitate in-depth exploration in this area.

 

circRNA Sponge represents a novel endogenous non-coding RNA, garnering widespread attention due to its capacity to regulate miRNA activity. Utilizing advanced artificial synthesis techniques, Abnova's circRNA Sponge products emulate the structure of endogenous circRNA and integrate multiple miRNA recognition elements (MREs) to enhance their binding capability with miRNAs, thereby modulating miRNA activity on target genes. In comparison to linear miRNA sponges, circRNA Sponge possesses distinct advantages, such as the absence of 5' and 3' UTR, low immunogenicity without the need for nucleotide modifications, and increased resistance to nucleases, ensuring improved adsorption stability and efficiency. Furthermore, circRNA Sponge overcomes the toxic concerns of traditional anti-miRNA oligonucleotides (AMO) and the dosage limitations associated with plasmid-based miRNA sponges.

 

Abnova introduces a novel circRNA Sponge product line, acting as miRNA sponges, offering diverse choices for researchers to meet their study demands. Our customized circRNA Sponge services ensure optimal outcomes in interaction analysis. Rely on Abnova's expert team for personalized design, synthesis, and validation, enabling profound research into circRNA Sponge-miRNA interactions. As a leading RNA solutions provider, we are committed to supporting scientific exploration and advancing circRNA Sponge-miRNA interaction analysis. With high-quality products and services, Abnova fosters breakthroughs in this field.

 

For detailed information, please visit the Abnova circRNA Sponge Customized Services webpage.

 

Abnova

+886-2-87511888

sales@abnova.com

Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)